Treatment News : FDA Approves Changes to Reyataz Label

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » February 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


February 13, 2013

FDA Approves Changes to Reyataz Label

The U.S. Food and Drug Administration (FDA) has approved changes to the label of the antiretroviral Reyataz (atazanavir) to include new warnings about kidney and gall stones, a kidney dysfunction known as interstitial nephritis, as well as updated drug interaction information.  

In a release, the FDA states that there have been anecdotal reports of kidney and gall stones (nephrolithiasis and cholelithiasis) among people taking Reyataz, which in some cases have required hospitalization. The FDA advises that if you experience signs or symptoms of kidney or gall stones, then you should consider a temporary interruption or discontinuation of the medication.

The FDA added interstitial nephritis, in which the spaces between the kidney tubules become inflamed, to the adverse reactions section of the Reyataz label.

The additional drug interactions include:

Boosted Reyataz (atazanavir/ritonavir) is not recommended with the hepatitis C antiviral Victrelis (boceprevir), as Victrelis can reduce levels of Reyataz.

The anticonvulsant Tegretol (carbamazepine) can reduce levels of Reyataz when it is taken without ritonavir; therefore, taking Tegretol and Reyataz without ritonavir is not recommended.

The antiepileptic Dilantin (phenytoin) or the barbiturate/anticonvulsant phenobarbital are not recommended in combination with Reyataz unless ritonavir is used as a booster to counteract a lowering of Reyataz levels.  

Reyataz and ritonavir taken together with the antiseizure drug Lamictal (lamotrigine) may decrease Lamictal levels, requiring a dose adjustment of Lamictal. Reyataz taken without ritonavir should not have this effect on Lamictal levels.

The antifungal medication Vfend (voriconazole) should not be taken with Reyataz/ritonavir without assessing the risks versus benefits, specifically the Vfend-related adverse effects and the loss of either Vfend or Reyataz’s efficacy. Voriconazole may affect Reyataz levels, but there is no available data to support this.

To read the FDA release, click here.

Search: HIV, U.S. Food and Drug Administration, FDA, antiretroviral, Reyataz, atazanavir, kidney stone, gall stone, nephrolithiasis, cholelithiasis, ritonavir, Victrelis, boceprevir, Tegretol, carbamazepine, Dilantin, phenytoin, phenobarbital, Lamictal, lamotrigine, Vfend, voriconazole.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.